CDTX
Price
$24.55
Change
-$1.15 (-4.47%)
Updated
May 23, 01:50 PM (EDT)
Capitalization
333.32M
GLMD
Price
$1.37
Change
-$0.00 (-0.00%)
Updated
May 23, 01:59 PM (EDT)
Capitalization
3.18M
76 days until earnings call
Interact to see
Advertisement

CDTX vs GLMD

Header iconCDTX vs GLMD Comparison
Open Charts CDTX vs GLMDBanner chart's image
Cidara Therapeutics
Price$24.55
Change-$1.15 (-4.47%)
Volume$140
Capitalization333.32M
Galmed Pharmaceuticals
Price$1.37
Change-$0.00 (-0.00%)
Volume$3.25K
Capitalization3.18M
CDTX vs GLMD Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. GLMD commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and GLMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (CDTX: $25.70 vs. GLMD: $1.37)
Brand notoriety: CDTX and GLMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 95% vs. GLMD: 0%
Market capitalization -- CDTX: $333.32M vs. GLMD: $3.18M
CDTX [@Biotechnology] is valued at $333.32M. GLMD’s [@Biotechnology] market capitalization is $3.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileGLMD’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • GLMD’s FA Score: 0 green, 5 red.
According to our system of comparison, both CDTX and GLMD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 6 TA indicator(s) are bullish while GLMD’s TA Score has 2 bullish TA indicator(s).

  • CDTX’s TA Score: 6 bullish, 4 bearish.
  • GLMD’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, CDTX is a better buy in the short-term than GLMD.

Price Growth

CDTX (@Biotechnology) experienced а +22.15% price change this week, while GLMD (@Biotechnology) price change was +8.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.81%. For the same industry, the average monthly price growth was +2.89%, and the average quarterly price growth was -3.16%.

Reported Earning Dates

CDTX is expected to report earnings on May 08, 2025.

GLMD is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+0.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($333M) has a higher market cap than GLMD($3.18M). CDTX YTD gains are higher at: -4.390 vs. GLMD (-57.053). GLMD has higher annual earnings (EBITDA): -6.7M vs. CDTX (-192.6M). CDTX has more cash in the bank: 168M vs. GLMD (17.1M). GLMD has less debt than CDTX: GLMD (41K) vs CDTX (2.67M). CDTX has higher revenues than GLMD: CDTX (302K) vs GLMD (0).
CDTXGLMDCDTX / GLMD
Capitalization333M3.18M10,459%
EBITDA-192.6M-6.7M2,876%
Gain YTD-4.390-57.0538%
P/E RatioN/A0.02-
Revenue302K0-
Total Cash168M17.1M982%
Total Debt2.67M41K6,520%
FUNDAMENTALS RATINGS
CDTX vs GLMD: Fundamental Ratings
CDTX
GLMD
OUTLOOK RATING
1..100
7636
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3691
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for CDTX (79) in the Biotechnology industry. This means that GLMD’s stock grew somewhat faster than CDTX’s over the last 12 months.

GLMD's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CDTX (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to CDTX’s over the last 12 months.

GLMD's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as CDTX (98) in the Biotechnology industry. This means that GLMD’s stock grew similarly to CDTX’s over the last 12 months.

CDTX's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for GLMD (91) in the Pharmaceuticals Other industry. This means that CDTX’s stock grew somewhat faster than GLMD’s over the last 12 months.

GLMD's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as CDTX (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXGLMD
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOVCX21.01N/A
N/A
First Trust/Confluence Small Cap Val C
JOSSX50.01N/A
N/A
Johnson Opportunity S
IUAEX27.32N/A
N/A
JPMorgan International Focus A
JEPCX13.84N/A
N/A
JPMorgan Equity Premium Income C
AAIPX17.40-0.01
-0.06%
American Beacon International Eq Inv

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with BPTSY. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then BPTSY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-2.10%
BPTSY - CDTX
92%
Closely correlated
-18.27%
REPL - CDTX
40%
Loosely correlated
+3.55%
CVAC - CDTX
36%
Loosely correlated
N/A
IVVD - CDTX
36%
Loosely correlated
-0.52%
INZY - CDTX
35%
Loosely correlated
N/A
More

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been closely correlated with XBIO. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLMD jumps, then XBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
N/A
XBIO - GLMD
88%
Closely correlated
N/A
IOBT - GLMD
35%
Loosely correlated
+8.11%
JSPR - GLMD
31%
Poorly correlated
+1.04%
CDTX - GLMD
28%
Poorly correlated
-2.10%
CRVS - GLMD
28%
Poorly correlated
-4.41%
More